| 6.28 0.41 (6.98%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.29 |
1-year : | 9.68 |
| Resists | First : | 7.09 |
Second : | 8.29 |
| Pivot price | 6.18 |
|||
| Supports | First : | 5.95 |
Second : | 5.25 |
| MAs | MA(5) : | 5.98 |
MA(20) : | 6.19 |
| MA(100) : | 5.67 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 17.2 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 7.19 | Low : | 2.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EPRX ] has closed below upper band by 39.3%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.36 - 6.4 | 6.4 - 6.44 |
| Low: | 5.79 - 5.84 | 5.84 - 5.87 |
| Close: | 6.22 - 6.29 | 6.29 - 6.35 |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Sat, 06 Dec 2025
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Sat, 06 Dec 2025
Analysts see more than 77% upside for Eupraxia Pharmaceuticals (EPRX), here’s why - MSN
Mon, 01 Dec 2025
Scotia Capital Inc. Reduces Stake in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
Thu, 27 Nov 2025
Eupraxia Pharmaceuticals Inc. $EPRX Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
Thu, 27 Nov 2025
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Mon, 17 Nov 2025
Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 37.2 (%) |
| Shares Short | 266 (K) |
| Shares Short P.Month | 256 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.3 % |
| Return on Equity (ttm) | -61.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -7.14 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|